BPC-157: What the Studies Show, Counted Out
Search for BPC-157 studies and you will find hundreds of papers and even more opinions. We like to count. How many studies, in what kind of animal or cell, by whom, and how many in people? This post answers those questions from two 2025 reviews and the registry records they point to. The answers are short, and the gaps are easy to see.
The molecule in one paragraph
BPC-157 is a synthetic peptide made of 15 amino acids. Chemists call a 15-residue chain a pentadecapeptide. The sequence was originally described from a protein found in gastric juice, which is why some papers call it a gastric peptide (McGuire et al., 2025). The research-grade material is produced by synthesis, not extracted from tissue. It arrives as a freeze-dried powder in a sealed vial.
What the animal literature covers
Almost all BPC-157 work is preclinical. A 2025 systematic review in orthopaedic sports medicine screened the field and included 36 studies. Thirty-five were preclinical and one was clinical (Vasireddi et al., 2025). That ratio is the single most useful fact about this compound.
The animal and cell studies fall into four groups:
- Tendon, ligament and muscle injury models. Rodents with a controlled injury, with recovery measured against untreated animals.
- Bone healing in animal models. Fracture and bone-defect studies.
- Gastrointestinal mucosal protection models. Studies of the stomach and gut lining under chemical or physical stress.
- Angiogenesis and nitric oxide signaling. Work on new blood-vessel growth and the nitric oxide pathway.
One city, most of the papers
Most of the preclinical literature comes from a single research group in Zagreb. A PubMed search run for our research summary returned 233 records for the compound, and 175 of them, about three in four, listed the same lead author. Consistency from one lab is not a flaw. Independent replication is what turns it into settled science, and there is not much of that yet.
The proposed mechanism
The honest headline is that the mechanism is not well established. The two 2025 reviews list several pathways that animal and cell studies have proposed:
- VEGFR2 and nitric oxide signaling, including the Akt-eNOS axis, which is linked to blood-vessel biology.
- ERK1/2, a signaling cascade involved in cell growth and survival.
- FAK-paxillin, a pathway tied to cell adhesion and movement.
- Growth hormone receptor expression in fibroblasts, the cells that build connective tissue.
Each of these comes from a model system. None has been confirmed as the operating mechanism in a person. When you see a confident one-line explanation of how BPC-157 acts, it is usually one of these four with the uncertainty removed.
The human reports, counted
This is where the count gets small. McGuire and colleagues identify three human pilot reports in the published record:
- A pilot report in people with knee pain.
- A pilot report in interstitial cystitis, a bladder condition.
- A pilot report on intravenous infusion in two adults, which looked at tolerability (Lee and Burgess, 2025).
Three reports, all small, none a large randomised controlled trial. The reviewers' own conclusion is that rigorous large-scale trials are lacking.
There is also one registry entry worth knowing about. A phase 1 study of an oral product containing BPC-157 was first posted on ClinicalTrials.gov in 2015 (NCT02637284). Its status is listed as unknown, and no results have been posted. A registry entry is a plan, not a finding.
WADA status
The World Anti-Doping Agency's 2026 Prohibited List names BPC-157 under section S0, non-approved substances. For anyone subject to anti-doping rules, that listing is the fact that matters. It is also a reminder that this is a research compound, not an approved medicine anywhere.
A regulatory footnote: FDA's list of bulk substances for compounding now places BPC-157 among substances that were nominated and later withdrawn by the nominators. Some 2025 reviews describe an earlier category for it. That description is out of date.
Where the studies stop
- Animal and cell models dominate: 35 of the 36 studies in the 2025 systematic review.
- Most preclinical papers come from one group.
- Human data are three small pilot reports. There are no large controlled trials.
- The mechanism is proposed, not established.
- WADA lists it as prohibited (S0).
That is not a verdict for or against the compound. It is a map of what has and has not been measured.
What "preclinical" means here
The word comes up in every section, so it deserves a plain definition. Preclinical research is everything that happens before a compound is tested in people under a controlled protocol: experiments in cells, in tissue samples and in animals. It is where ideas about mechanism come from, and it is a necessary first step. It is not evidence about people. For BPC-157, almost the entire record sits in this stage. The three pilot reports are the only published steps past it, and they are small enough that the reviewers do not treat them as settled findings.
What a BPC-157 lot certificate shows
A 15-residue peptide has one expected molecular mass. Mass spectrometry (MS) checks that the material in the vial matches it, which confirms identity. High-performance liquid chromatography (HPLC) then separates the main peak from anything else and reports a measured purity. We do not quote a single figure for every vial. Each lot's certificate states its own measured purity and identity, along with the lot number and test date. Check that the lot number on the certificate matches the vial.
BPC-157 is also one half of our BPC-157 + TB-500 blend. A blend certificate confirms each component separately, because the two compounds have separate literatures.
Storage
Keep sealed vials of the freeze-dried powder cool, dry and out of direct light. Allow a cold vial to warm to room temperature before opening to avoid condensation. These are laboratory storage notes, not instructions for use.
BPC-157 at a glance
| Item | Detail |
|---|---|
| Type | Synthetic pentadecapeptide (15 amino acids) |
| Origin of sequence | Described from a protein in gastric juice |
| Research areas | Tendon, ligament and muscle models; bone healing models; gut mucosal protection models; angiogenesis and nitric oxide signaling |
| Human reports | Three small pilot reports; one phase 1 registry entry with unknown status |
| Research stage | Mainly preclinical |
| WADA | Prohibited, S0 non-approved substances |
| Format | Lyophilised powder, single vial |
Frequently asked questions
Has BPC-157 been studied in humans?
Only in a small way. Published human data consist of three small pilot reports, covering knee pain, interstitial cystitis and intravenous infusion in two adults. A 2015 phase 1 registry entry has unknown status and no posted results. There are no large controlled trials.
Why does one research group publish most of the BPC-157 papers?
The compound has been the long-running focus of a group in Zagreb. About three in four PubMed records list the same lead author. Independent replication from other labs is still limited.
Is BPC-157 prohibited in sport?
Yes. WADA's 2026 Prohibited List names it under S0, non-approved substances.
How is a BPC-157 lot checked?
Mass spectrometry confirms the identity against the expected mass of the 15-residue peptide, and HPLC reports a measured purity. Both appear on the lot's certificate of analysis with the lot number and test date.
See it in the catalogue: BPC-157.
For laboratory research use only. Products sold by Amino Party Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.